A thorough analysis of highly clinically relevant PGx genes in a single assay
Use of pharmacogenomics (PGx) information in the clinical trials has the potential to enable pharmaceutical companies to develop safer and more effective drugs. PharmacoFocusTM assay offers a thorough investigation of high-evidence, and highly clinically relevant PGx genes (Pharmacogenomics Knowledge Base (PharmGKB) clinical annotation level of evidence 1A-2B) that leads to better understanding of participant’s drug responses. The assay potentially reduces the lengthy timeline and complexities within the drug discovery process.
2,000+ markers in 150 ADME genes covering population diversity
Comprehensive Investigation of high-evidence pharmacogenomic research markers (PharmGKB clinical annotation level 1A-2B)
Copy number variation (CNV) analysis with high resolution copy number calls (0 to 3+) for the key ADME genes: CYP2D6, CYP2A6, GSTMT1, GSTT1, and UGB2B17.
Accurate genotyping of highly predictive markers in regions of high homology within CYP2C19, CYP2C8, CYP2D6, CYP2A6, CYP2B6, and GSTM1
900+ unique star alleles/haplotypes across 66 PGx genes
Highly accurate and reproducible clinically focused genotyping solution
RPRD is proud to be the early access site and first clinical laboratory to offer PharmacoFocusTM assay as a fully CLIA-certified diagnostic test. RPRD’s PharmacoFocusTM solution shows2
Highly accurate and reproducible testing results using various specimens, such as whole blood and saliva.
Accurate copy number calling for highly actionable genes, such as CYP2D6
Comprehensive HLA analysis with high resolution of typing (2-digit and 4-digit) of the major histocompatibility complex (3 MHC Class I and 8 Class II) loci, including HLA-A* and HLA-B* types with known relevance in drug metabolism